EVOK
Evoke Pharma, Inc.11.00
+0.04+0.37%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
18.95MP/E (TTM)
-Basic EPS (TTM)
-1.38Dividend Yield
0%Recent Filings
8-K
10-Q
Q2 FY2025 results
Evoke Pharma's Q2 net product sales climbed 47% y/y to $3.8M, fueled by expanded pharmacy networks and higher refill rates, while YTD sales rose 59% to $6.8M versus prior year. Gross margins held steady despite a 304% y/y jump in cost of goods sold to $0.2M, tied to stability testing timing, but operating losses widened 27% y/y to $1.6M amid surging SG&A from Eversana profit sharing. Diluted EPS improved to $(0.62) from $(0.93), reconciling with 2.55M weighted shares; net loss tracked operating loss closely, with minimal other expense drag from interest. Cash dipped to $12.1M after $1.6M operating burn, offset by minor ESPP inflows, while the $5.0M Eversana note at 10%—now current due to termination risk—looms large alongside $7.4M total debt. No non-GAAP metrics disclosed in the 10-Q. Yet regulatory pressures from the Inflation Reduction Act threaten pricing power.
8-K
Q2 sales surge 47%
Evoke Pharma reported Q2 2025 net product sales of $3.8 million, up 47% from $2.6 million in Q2 2024, fueled by 20% growth in new prescribers and steady 70% refill rates for GIMOTI. While net loss widened to $1.6 million from $1.3 million due to higher selling expenses, cash reserves stood at $12.1 million, funding operations into Q3 2026. Sales are accelerating. The company reaffirmed 2025 guidance of $16 million in net sales, but risks like supply chain issues loom.
8-K
New GIMOTI patent issued
Evoke Pharma announced the issuance of U.S. Patent No. 12,377,064 on August 6, 2025, covering intranasal metoclopramide for moderate to severe gastroparesis symptoms in its GIMOTI product. The patent extends protection to November 2038, bolstering IP defenses. Evoke plans Orange Book listing. This strengthens market exclusivity amid IP maintenance risks.
8-K
Patent extends GIMOTI exclusivity
Evoke Pharma snagged a USPTO Notice of Allowance on July 9, 2025, for a patent covering GIMOTI use in moderate to severe gastroparesis patients, extending exclusivity to December 2036 via Orange Book listing. This bolsters IP around intranasal metoclopramide, a key edge for the non-oral therapy amid oral absorption woes. Yet risks loom if FDA listing falters. Patent protection lasts until 2036.
IPO
Website
Employees
Sector
Industry
EBS
Emergent BioSolutions Inc.
12.19-0.14
ELTP
Elite Pharmaceuticals, Inc.
0.50+0.00
EOLS
Evolus, Inc. Common Stock
7.22+0.08
EVFM
Evofem Biosciences, Inc.
0.01-0.00
EVO
Evotec SE
3.01+0.03
NSRX
Nasus Pharma Ltd.
6.80+0.00
SBFM
Sunshine Biopharma Inc.
1.38-0.01
TAK
Takeda Pharmaceutical Company L
14.53-0.08
TEVA
Teva Pharmaceutical Industries
30.10-0.03
XERS
Xeris Biopharma Holdings, Inc.
7.10+0.05